These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35610080)

  • 1. Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.
    Yu X; Gu M; Zhu Y; Zhang L; Kong W; Zou Y
    Clin Ther; 2022 May; 44(5):723-735.e6. PubMed ID: 35610080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
    Zhang S; Xie Q; Xie S; Chen J; Deng Q; Zhong L; Guo J; Yu Y
    Pharmacotherapy; 2021 Sep; 41(9):781-791. PubMed ID: 34170566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
    Sapankaew T; Thadanipon K; Ruenroengbun N; Chaiyakittisopon K; Ingsathit A; Numthavaj P; Chaiyakunapruk N; McKay G; Attia J; Thakkinstian A
    BMC Nephrol; 2022 Jun; 23(1):223. PubMed ID: 35739495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4-5 chronic kidney disease not yet on dialysis: A meta-analysis of observational studies.
    Jeong HJ; Park WY; Kim SH; Dalbeth N; Son CN
    Semin Arthritis Rheum; 2022 Oct; 56():152073. PubMed ID: 35914389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials.
    Sun SS; Zhang DH; Shi Y; Lin CJ; Lin JY
    J Clin Pharm Ther; 2020 Aug; 45(4):729-742. PubMed ID: 32406077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial.
    Kohagura K; Satoh A; Kochi M; Nakamura T; Zamami R; Tana T; Kinjyo K; Funakoshi R; Yamazato M; Ishida A; Sakima A; Iseki K; Arima H; Ohya Y
    J Hypertens; 2023 Sep; 41(9):1420-1428. PubMed ID: 37334544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Drug Treatments for Lowering Uric Acid on Renal Function in Patients With Chronic Kidney Disease and Hyperuricemia: A Network Meta-Analysis of Randomized Controlled Trials.
    Liu X; Qiu Y; Li D; Tan J; Liang X; Qin W
    Front Pharmacol; 2021; 12():690557. PubMed ID: 34413775
    [No Abstract]   [Full Text] [Related]  

  • 8. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
    Hu AM; Brown JN
    Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
    Yang N; Cao B
    J Clin Pharm Ther; 2022 Dec; 47(12):2214-2222. PubMed ID: 36403976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
    Tsukamoto S; Okami N; Yamada T; Azushima K; Yamaji T; Kinguchi S; Uneda K; Kanaoka T; Wakui H; Tamura K
    Clin Rheumatol; 2022 Mar; 41(3):911-919. PubMed ID: 34642880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease.
    Tiku A; Johnson DW; Badve SV
    Curr Opin Nephrol Hypertens; 2021 May; 30(3):346-352. PubMed ID: 33767063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
    Kim SH; Lee SY; Kim JM; Son CN
    Korean J Intern Med; 2020 Jul; 35(4):998-1003. PubMed ID: 30959584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
    Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
    Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis.
    Li S; Yang H; Guo Y; Wei F; Yang X; Li D; Li M; Xu W; Li W; Sun L; Gao Y; Wang Y
    Sci Rep; 2016 Sep; 6():33082. PubMed ID: 27605442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
    Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
    Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To Treat or Not to Treat? Effect of Urate-Lowering Therapy on Renal Function, Blood Pressure and Safety in Patients with Asymptomatic Hyperuricemia: A Systematic Review and Network Meta-Analysis.
    Tien YY; Shih MC; Tien CP; Huang HK; Tu YK
    J Am Board Fam Med; 2022; 35(1):140-151. PubMed ID: 35039419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic Kidney Disease.
    Nagaraju SP; Shenoy SV; Rao I; Prabhu RA; Rangaswamy D; Bhojaraja MV; Guddattu V
    Saudi J Kidney Dis Transpl; 2023 Jul; 34(4):279-287. PubMed ID: 38345582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes: A Systematic Review and Meta-Analysis.
    Chen Q; Wang Z; Zhou J; Chen Z; Li Y; Li S; Zhao H; Badve SV; Lv J
    Clin J Am Soc Nephrol; 2020 Nov; 15(11):1576-1586. PubMed ID: 33055192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials.
    Lin YJ; Lin SY; Lin CH; Wang ST; Chang SS
    Clin Rheumatol; 2020 May; 39(5):1633-1648. PubMed ID: 31965378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.